ABIONYX Pharma SA (FRA:609)

Germany · Delayed Price · Currency is EUR

2.005

-0.095 (-4.52%)

Last updated: Jun 26, 2026, 8:08 AM CET

71.66% (1Y)

Market Cap	72.00M +66.6%
Revenue (ttm)	4.06M -10.7%
Net Income	-5.55M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.005
Previous Close	2.100
Day's Range	2.005 - 2.005
52-Week Range	1.126 - 5.000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2005

Employees 49

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 609

Financial Performance

In 2025, ABIONYX Pharma's revenue was 4.06 million, a decrease of -10.72% compared to the previous year's 4.55 million. Losses were -5.55 million, 26.7% more than in 2024.

Financial Statements